Evidence Hub

Vitreal penetration of oral and topical moxifloxacin in humans

Fuller JJ, Lott MN, Henson NM, Bhatti AA, Singh H, McGwin G, Marcus DM

American journal of ophthalmology, 2007

8 participants

Abstract

PURPOSE: To investigate the vitreal penetration of moxifloxacin after oral and topical administration.

DESIGN: Prospective, nonrandomized clinical trial.

METHODS: Twenty-four patients were assigned to one of four dosing groups: control (n = 3), which received no medication; oral (n = 8), which received two 400 mg oral doses of moxifloxacin before surgery; topical (n = 8), which received one drop of topical moxifloxacin 0.5% every 15 minutes for the hour preceding surgery; and combined (n = 5), which received two 400 mg oral doses and one drop of topical moxifloxacin 0.5% hourly for 18 hours prior to surgery. Vitreous samples were obtained and analyzed.

RESULTS: Control, below quantifiable levels; oral, 1.553 +/- 0.33 microg/ml; topical, 0.027 microg/ml; and combined, 2.219 +/- 0.71 microg/ml. One topical patient developed postoperative endophthalmitis.

CONCLUSIONS: In contrast to topical moxifloxacin, oral moxifloxacin achieves significant levels in the noninflamed human vitreous.

How strong is the evidence?

Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 8 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free